Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Need for further surgery particularly high in younger men and serious complications surprisingly common in older people, say researchers.

The risks associated with shoulder replacement surgery for arthritic conditions are higher than previously estimated, particularly for people under 60 and over 85 years old, finds a study published by The BMJ today.

“The decision to undergo a shoulder replacement is a balance between the potential benefits and possible risks of surgery. 
- Richard Craig, lead author 

The findings show that one in four men aged 55-59 years is at risk of needing further revision surgery, especially during the first five years after surgery. What’s more, the risks of serious adverse events (such as heart attacks, major blood clots and chest infections) within 90 days of surgery are much higher than previously estimated, particularly in those over 85 years. 

The researchers say these risks should be made clearer to patients before they opt for surgery, and they caution against “unchecked expansion” of shoulder replacement surgery in both younger and older patients.

“The decision to undergo a shoulder replacement is a balance between the potential benefits and possible risks of surgery. We hope that patients and surgeons will use the information from our study to help them decide whether to go ahead with a shoulder replacement for arthritis.”, says lead author Richard Craig.

The number of shoulder replacements performed is expanding rapidly. In adults aged over 50, surgery increased more than 5.6-fold, from 1,018 cases in 1998 to 5,691 in 2016.

Despite this growth, no study has reported on the lifetime risk of further surgery, and serious events are considered rare.

So our researchers used hospital and mortality records to calculate precise risk estimates of serious adverse events and lifetime risk of revision surgery, after non-emergency (elective) shoulder replacement surgery for arthritis.

The study included just over 58,000 procedures carried out in nearly 52,000 adults (aged 50 or over) across England between April 1998 and April 2017. Average age at surgery was 72 years and average follow-up was 5.6 years.

Rates of serious adverse events were calculated at 30 and 90 days after surgery and included major blood clots, heart attack, infections, stroke and death. Revision risk according to age and sex was estimated at 3, 5, 10, and 15 years after surgery and over a patient’s lifetime.

The lifetime risk of revision surgery ranged from 1 in 37 in women aged 85 years and older to 1 in 4 in men aged 55-59 years. The risks of revision were highest during the first five years after surgery. 

The risk of any serious adverse event at 30 days post-surgery was 1 in 28, and at 90 days post-surgery was 1 in 22. 

Serious adverse events were associated with increasing age, existing illness (comorbidity), and male sex - 1 in 9 women and 1 in 5 men aged 85 years and older experienced at least one serious adverse event within 90 days.

This is an observational study, and as such, can’t establish cause, and the researchers cannot rule out the possibility that some unmeasured factors may have influenced the results. 

Nevertheless, they say these risks are higher than previously considered, and for some could outweigh any potential benefits.

They say younger patients, particularly men, need to be aware of a higher likelihood of early failure of shoulder replacement and the need for further and more complex revision replacement surgery. And they suggest that all patients should be counselled about the risks of serious adverse events. 

As the population ages, it is likely that demand for shoulder replacement in older people will continue to increase, and the higher risk of adverse events described here should form part of shared decision making with patients, they conclude. 

 

Supported by

Royal College of Surgeons logo

Versus Arthritis logo

   NIHR logo

National Joint Registry logo

Similar stories

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers at NDORMS have developed a new set of guidelines for reporting mediation analyses in health research.

New Associate Professors announced at NDORMS

The Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS.

COVID-19 vaccines shown to reduce infection by 90% in nursing homes

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Unlocking the secrets of the microbiome

Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Research explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.

Into the future: watching biology unfold

As part of the University of Oxford’s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.